BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?

ABSTRACT:

Purpose

Bacille Calmette-Guérin (BCG) is a well-established treatment for preventing or delaying tumour recurrence following high-grade nonmuscle invasive bladder cancer (NMIBC) resection. However, many patients will experience recurrence or progression during or following BCG. This scenario has been one of the most challenging in urologic oncology for several decades since BCG implementation. Finally, significant progress has occurred lately. The aim of this review was to summarize for the practising urologist the current treatment options available in 2020 or expected to be ready for routine use in the near future for patients with high-risk NMIBC who experience BCG failure.

Methods

Narrative review using data through the end of 2020.

Results

First, the definition o

SUBMITTER: Lebacle C 

PROVIDER: S-EPMC7997797 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature